Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study
Tessa Dieckman, Michael Schümann, Hanneke Beaumont, Hetty J. Bontkes, Frits Koning, Gerd Bouma, Valerie Byrnes, Jane McCarthy, Andra Neefjes-Borst, Christoph Loddenkemper, Jeroen van Bergen, Marlous op de Weegh, K.E.A. Lundin
Abstract
who had failed previous therapies were treated in the Netherlands with tofacitinib 10 mg twice-daily for 12 weeks (Methods; Supporting Documents). Two patients in Germany who fulfilled the inclusion criteria received similar treatment outside this protocol.
Topics & Concepts
MedicineTofacitinibRefractory (planetary science)Open labelGastroenterologyInternal medicineComplete remissionClinical trialChemotherapyPhysicsAstrobiologyRheumatoid arthritisCeliac Disease Research and ManagementMicroscopic ColitisMicrobial Metabolites in Food Biotechnology